Genscript Biotech Corporation announced that, (i) Mr. Pan Yuexin has resigned as a non-executive Director with effect from 21 June
2024 due to his attainment of statutory retirement age, and (ii) Mr. Guo Hongxin has resigned as an independent non-executive Director with effect from 21 June 2024 due to having served as an independent non-executive Director for nine years by 24 August 2024. The Board further announced that, with effect from 21 June 2024, (i) Mr. Pan Yuexin ceased to be a member of
the Strategy Committee and (ii) Mr. Guo Hongxin ceased to chair the Remuneration Committee and ceased to be a member of the Audit Committee and the Risk Management and ESG Committee respectively. With effect from 21 June 20234, (i) Mr. Cheung Yiu Leung Andy will be appointed as a new member of the Audit Committee, (ii) Mr. Dai Zumian will be re-designated from a member of the Remuneration Committee to the chairman of the Remuneration Committee and Dr. Shi Chenyang will be appointed as a new member of the Remuneration Committee, (iii) Mr. Cheung Yiu Leung Andy will be appointed as a new member of the Risk
Management and ESG Committee and (iv) Mr. Dai Zumian and Mr. Pan Jiuan will be appointed as new members of the Strategy Committee.